ABBV vs ELV
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. ELV: Elevance Health is a leading health benefits and services organization providing comprehensive medical, pharmacy, and integrated clinical care solutions to millions of members.
Side-by-side fundamentals
| Metric | ABBV | ELV | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $264.52 | $402.63 | |
| Market cap as of 2026-08-24 | $467.4B | $87.3B | |
| P/E as of 2026-08-24 | 74.32 | 17.89 | ELV lower |
| PEG as of 2026-08-24 | 6.59 | 3.95 | ELV lower |
| Net margin as of 2026-08-24 | +9.8% | +2.5% | ABBV higher |
| Gross margin as of 2026-08-24 | +72.8% | n/a | |
| Operating margin as of 2026-08-24 | +26.2% | +3.6% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | +11.2% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +4.0% | ABBV higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.69 | ELV lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +6.3% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +8.3% | ELV higher |
| Dividend yield as of 2026-08-24 | +4.5% | +1.2% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.27 | 0.22 | |
| 1-year return as of 2026-08-24 close | +25.6% | +27.2% | ELV higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.